Amneal Pharmaceuticals, Inc.
AMRX
$7.41
-$0.40-5.12%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 730.52M | 702.47M | 701.78M | 659.19M | 616.98M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 730.52M | 702.47M | 701.78M | 659.19M | 616.98M |
| Cost of Revenue | 468.58M | 434.88M | 452.88M | 422.12M | 391.50M |
| Gross Profit | 261.94M | 267.59M | 248.91M | 237.08M | 225.48M |
| SG&A Expenses | 128.69M | 118.69M | 116.46M | 112.60M | 109.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | 0.00 |
| Total Operating Expenses | 651.53M | 614.67M | 605.39M | 574.01M | 546.59M |
| Operating Income | 78.99M | 87.80M | 96.39M | 85.18M | 70.39M |
| Income Before Tax | -15.32M | 15.42M | 20.41M | -75.52M | -83.46M |
| Income Tax Expenses | 5.42M | 3.67M | 3.62M | 6.16M | 9.88M |
| Earnings from Continuing Operations | -20.74M | 11.76M | 16.79M | -81.68M | -93.34M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -10.34M | -11.91M | -10.79M | -9.97M | -5.31M |
| Net Income | -31.08M | -156.00K | 5.99M | -91.64M | -98.65M |
| EBIT | 78.99M | 87.80M | 96.39M | 85.18M | 70.39M |
| EBITDA | 145.12M | 146.76M | 151.96M | 140.71M | 127.33M |
| EPS Basic | -0.10 | 0.00 | 0.02 | -0.30 | -0.40 |
| Normalized Basic EPS | -0.07 | -0.01 | 0.00 | 0.01 | 0.01 |
| EPS Diluted | -0.10 | 0.00 | 0.02 | -0.30 | -0.40 |
| Normalized Diluted EPS | -0.07 | -0.01 | 0.00 | 0.01 | 0.01 |
| Average Basic Shares Outstanding | 309.85M | 309.65M | 309.12M | 307.28M | 243.71M |
| Average Diluted Shares Outstanding | 309.85M | 309.65M | 318.96M | 307.28M | 243.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
